Gilead Sciences
149,05 $Variazione rispetto alla chiusura precedente: −1,47%Variazione assoluta: −2,23 $
Ultime notizie
Titoli nella lingua originale della fonte.
- More Upside Awaits for Gilead Sciences Stock. Stay Invested. (si apre in una nuova scheda)
- Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD (si apre in una nuova scheda)
- Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (si apre in una nuova scheda)
- ETFs Bought $76.5 Million of Gilead Sciences (GILD) on Sept. 29 (si apre in una nuova scheda)
- Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research (si apre in una nuova scheda)
- Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors (si apre in una nuova scheda)
- Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors (si apre in una nuova scheda)
- Gilead Sciences (GILD) Tests Its Multi Platform Story On Questions Around Valuation (si apre in una nuova scheda)
- Gilead Sciences (NDQ:GILD): Fighting HIV/AIDS Is Its Economic Engine (si apre in una nuova scheda)
- Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings (si apre in una nuova scheda)
- Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors (si apre in una nuova scheda)
- Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? (si apre in una nuova scheda)
- Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? (si apre in una nuova scheda)
- Gilead Sciences stock last trades at USD 152.43 on September 28, 2026 (si apre in una nuova scheda)
- Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? (si apre in una nuova scheda)
- Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook? (si apre in una nuova scheda)
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir (si apre in una nuova scheda)
- Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? (si apre in una nuova scheda)
- Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? (si apre in una nuova scheda)
- Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? (si apre in una nuova scheda)
- Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? (si apre in una nuova scheda)
- Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? (si apre in una nuova scheda)
- Form 4 Gilead Sciences Inc For: 26 September By Investing.com (si apre in una nuova scheda)
- Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts (si apre in una nuova scheda)
- Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close (si apre in una nuova scheda)
- UBS Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $175 (si apre in una nuova scheda)
- Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. (si apre in una nuova scheda)
- Gilead Sciences stock heads into the open after a 0.4 percent gain (si apre in una nuova scheda)
- Does Expanded HIV Prevention Access Change The Bull Case For Gilead Stock (GILD)? (si apre in una nuova scheda)
- Why Gilead can’t stop talking about its ambitions in immunology (si apre in una nuova scheda)